AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05003648 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT05634109 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Transfusion of blood products
Description: The intervention will be either a) administration of 6 units of whole blood or b) administration of blood component therapy in the proportion of 6:6:6 units of red blood cells, plasma, and platelets.
Study NCT05634109 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transfusion of blood products
Description: The intervention will be either a) administration of 6 units of whole blood or b) administration of blood component therapy in the proportion of 6:6:6 units of red blood cells, plasma, and platelets.
Study NCT04852003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0410 Injection
Description: SHR0410 Injection
Study NCT04852003 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for SHR0410 Injection
Study NCT04852003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine
Study NCT04862078 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Shared decision making
Description: Shared decision making and decide surveillance strategy between standard follow-up according to the institutional practice and decide what to do advanced imagings for surveillance and guideline-based surveillance
Study NCT04862078 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Usual care
Description: standard follow-up according to the institutional practice
Study NCT06458439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: * C1D1: fixed priming dose of 0.16 mg subcutaneous injection~* C1D8: fixed intermediate dose of 0.8 mg subcutaneous injection~* C1D15 onward: fixed full dose of 48 mg subcutaneous injection
Study NCT05718778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piamprimab (AK105)
Description: Piamprilizumab (AK105) combined with radiotherapy for neoadjuvant treatment of soft tissue sarcoma
Study NCT04986332 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity program
Description: 24-weeks moderate-intensity physical activity program
Study NCT04986332 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity program
Description: 24-weeks moderate-intensity physical activity program
Study NCT04986332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global therapeutic remodeling
Description: Re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions
Study NCT04986332 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Global therapeutic remodeling
Description: Re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions
Study NCT05886543 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional chest physical therapy
Description: Conventional chest physical therapy: The patients performed four series of five breath with 3 seconds of sustained breathing interspersed with periods of quite breathing followed by two or three coughs or huffs (with wound support by a pillow or his/her hands), twice a day in the first two postburned days and once a day from the third to the tenth days.
Study NCT05886543 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pilates exercise
Description: The Pilates technique, which stretched laterally and to the back, stressed costal breathing, in which the ribs climb and drop throughout the ventilatory stream. The transverse muscle had to work harder to avoid abdominal distension, provide more support to the diaphragm to promote lower rib movement, and provide more diaphragmatic excursion, During the expiratory phase, the transversus abdominis, the multifidus and the pelvic floor musculature were contracted.
Study NCT06346210 — intervention group
Intervention type: PROCEDURE
Intervention: Tracheostomy
Description: Surgery for tracheostomy
Study NCT06387147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin
Description: Gentamicin 80 mg 3 times per day during 14 days oral route or nasogastric tube or jejunostomy tube (in the case of an ostomy)
Study NCT06387147 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gentamicin placebo (2ml sodium chloride diluted 1/10 in a syringe of 20mL Metronidazole placebo in tablets
Study NCT06387147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Métronidazole 500mg 3 times per day during 14 days oral route or nasogastric tube or jejunostomy tube (in the case of an ostomy)
Study NCT06121037 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: proximal ultrasound-guided GON radiofrequency ablation
Description: proximal GON radiofrequency
Study NCT06121037 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: distal ultrasound-guided GON radiofrequency ablation
Description: distal GON radiofrequency
Study NCT05190510 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Collection of data from preoperative imaging examinations (routine examination prescribed before the operation)
Study NCT05190510 — intervention group
Intervention type: PROCEDURE
Intervention: collection of the carotid plaque (surgical specimen)
Description: collection of the carotid plaque
Study NCT05190510 — intervention group
Intervention type: OTHER
Intervention: anatomopathological, histological, cellular and molecular biology examinations (metabolomics and transcriptomics) on surgical specimens
Description: anatomopathological, histological, cellular and molecular biology examinations (metabolomics and transcriptomics) on surgical specimens
Study NCT06268522 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Oriented Recovery Enhancement: (MORE) group
Description: Mindfulness-Oriented Recovery Enhancement (MORE) is a novel social work intervention and mental training program that unites complementary aspects of mindfulness training.
Study NCT06268522 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychoeducation
Description: Education on the neurobiology of pain, healthy eating, diet, sleep and stress
Study NCT04018625 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART Mom
Description: SMART Pregnancy is an 8-session online stress management program offered in a group format. SMART Pregnancy is an adaptation of the Stress Management and Resiliency Training Program (Park et al., 2012).
Study NCT04018625 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mama Support
Description: Participants will be enrolled in an 8-week time and attention matched, process-based support group.
Study NCT05769530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine，dexmedetomidine
Description: According to the drug use, the subjects were divided into group A, which was continuously injected with normal saline during the operation, and intravenously injected with 5 mL normal saline 30 minutes before the end of the operation. In group B, DEX 0.5μg/kg was injected intravenously during the operation, which was completed in 10 min, and Nalbuphine 0.20 mg/kg (5 mL) was injected intravenously 30min before the end of the operation. After the operation, all anesthetic drugs were stopped and the patient was transferred to PACU with intubation.
Study NCT05769530 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nalbuphine，dexmedetomidine
Description: According to the drug use, the subjects were divided into group A, which was continuously injected with normal saline during the operation, and intravenously injected with 5 mL normal saline 30 minutes before the end of the operation. In group B, DEX 0.5μg/kg was injected intravenously during the operation, which was completed in 10 min, and Nalbuphine 0.20 mg/kg (5 mL) was injected intravenously 30min before the end of the operation. After the operation, all anesthetic drugs were stopped and the patient was transferred to PACU with intubation.
Study NCT05510648 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high-intensity laser therapy
Description: A total of 15 sessions of hotpack, TENS and exercise program will be applied to the patients for three weeks, 5 days a week, 1 session a day. The patients in the HILT group will be treated with a BTL 6000 brand device (Figure 5) for 3 sessions of high-intensity laser with a power of 10.0 w in the first week, energy density of 12 j/cm², every 25 cm² for 2 minutes in analgesic mode, and 5 sessions in the following 2 weeks. While 6 sessions of .0 w power, energy density of 120 j/cm², each 25 cm² for 10 minutes, will be applied in biostimulant mode for 6 sessions for three weeks, is applied in analgesic mode for 3 sessions every other day in the first week, and 6 sessions every other day in the biostimulant mode for the next two weeks, for a total of 9 sessions for three weeks.
Study NCT05510648 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: high-intensity laser therapy
Description: A total of 15 sessions of hotpack, TENS and exercise program will be applied to the patients for three weeks, 5 days a week, 1 session a day. The patients in the HILT group will be treated with a BTL 6000 brand device (Figure 5) for 3 sessions of high-intensity laser with a power of 10.0 w in the first week, energy density of 12 j/cm², every 25 cm² for 2 minutes in analgesic mode, and 5 sessions in the following 2 weeks. While 6 sessions of .0 w power, energy density of 120 j/cm², each 25 cm² for 10 minutes, will be applied in biostimulant mode for 6 sessions for three weeks, is applied in analgesic mode for 3 sessions every other day in the first week, and 6 sessions every other day in the biostimulant mode for the next two weeks, for a total of 9 sessions for three weeks.
Study NCT05510648 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sham high-intensity laser therapy
Description: Hotpack, TENS and exercise program applications will be applied to the patients in the same way as in the HILT group, 5 days a week, 1 session a day, a total of 15 sessions for three weeks. HILT is administered as a placebo for three weeks, 3 sessions a week, every other day, for a total of 9 sessions.
Study NCT05510648 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham high-intensity laser therapy
Description: Hotpack, TENS and exercise program applications will be applied to the patients in the same way as in the HILT group, 5 days a week, 1 session a day, a total of 15 sessions for three weeks. HILT is administered as a placebo for three weeks, 3 sessions a week, every other day, for a total of 9 sessions.
Study NCT04586621 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Atoldys/ Lexilens - SHAM
Description: Atoldys/ Lexilens: glasses with specific light frequency SHAM: glasses with no frequency
Study NCT04586621 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SHAM- Atoldys/ Lexilens
Description: SHAM: glasses with no frequency Atoldys/ Lexilens: glasses with specific light frequency
Study NCT04670913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: A human anti-PD-1 monoclonal antibody
Study NCT04670913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: A tyrosine kinase inhibitor selectively targeting VEGFR-2
Study NCT05375175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hybrid Snack
Description: The intervention will consist of the administration of 20 g of the snack (produced by Fertinagro Company) that will be eaten at fasting in the morning. Participants will be fasting for 12 hours for solid or liquid food and more than 1 hour after ingestion of water. Blood samples will be obtained after venepuncture at 7:45 a.m. before eating snacks and 15, 30, 60, 90 and 120 minutes after it.~Hybrid snack: combination of legumes in the highest proportion and lean meat.~It will have the following composition:~Ingredients (%):~Chickpea flour 45.40% Natural emulsifier 0.40% Meat 15.50% Olive oil 1.00% Sunflower oil 4.00% Water 22.50% Onion powder 0.30% Garlic powder 0.20% Thyme 0.60% Tomato powder 10.00%
Study NCT05375175 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meat snack
Description: The intervention will consist of the administration of 20 g of the snack (produced by Fertinagro Company) that will be eaten at fasting in the morning. Participants will be fasting for 12 hours for solid or liquid food and more than 1 hour after ingestion of water. Blood samples will be obtained after venepuncture at 7:45 a.m. before eating snacks and 15, 30, 60, 90 and 120 minutes after it.~Snack sausage:~Composed solely of meat from loin tape~It will have the following composition:~Ingredients (%):~Shoulder meat 4 mm 94.13% Low sodium salt 3.30% Maltodextrin 1.65% Spices 0.28% Natural dye 0.64%
Study NCT05395858 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Retrospective analysis using database without any intervention assigned in the study.
Study NCT05303909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin
Description: a single dose of IV gentamicin at a dose of 5 mg/kg infused over 30 minutes via a peripheral vein. Followed by administration of YF17D vaccine (stamaril) 0.5mls via subcutaneous injection into the deltoid region of the right or left arm.
Study NCT05303909 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100mls of 0.9% normal saline as placebo infused over 30 minutes via a peripheral vein. Followed by administration of YF17D vaccine (stamaril) 0.5mls via subcutaneous injection into the deltoid region of the right or left arm.
Study NCT05543148 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Evaluate hearing loss and communication and conversation disabilities
Study NCT04813809 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BARRIER EasyWarm
Description: Application of BARRIER EasyWarm for 10 hours. The treatment with the investigational device will be according to the instruction stated on the investigational device.
Study NCT05075564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1 ES002023
Description: ES002023 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
Study NCT05075564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2 ES002023
Description: ES002023 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
Study NCT05813028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a Mobile Application
Description: Patients will use the mobile application for 6 weeks after receiving the first course of chemotherapy. The Multidimensional Scale of Perceived Social Support, Memorial Symptom Rating Scale, EORTC QLQ-C30 Quality of Life Scale and QLQ-CR29 Module, Beck Anxiety Scale will be administered when they come to the hospital for their 2nd course of chemotherapy. Patients will use the mobile application for 6 more weeks after receiving the second chemotherapy course. 3. The scales will be reapplied when they come to the hospital for a chemotherapy course. Patients will continue to use the mobile application for three more weeks after receiving their 4th and final cure. When the patients come to the outpatient clinic control in the 12th week, the use of the mobile application will be terminated and the Mobile Application Efficiency Evaluation Form will be applied together with the other scales.
Study NCT05063500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicyclol, 25mg/ tablet
Description: Experimental group: each oral bicyclol 50mg, three times daily for 4 weeks.
Study NCT05063500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyene phosphatidylcholine capsules, 228mg/ particle.
Description: Control group: each oral polyene phosphatidylcholine 456mg, three times daily for 4 weeks.
Study NCT05129852 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sage oil group
Description: Sometimes called muscatel. Made by steam or water distillation of Salvia sclarea flowering tops and foliage. Yields range from 0.7 to 1.5%. A pale yellow to yellow liquid with a herbaceous odor and a winelike bouquet. Produced in large quantities in France, Russia and Morocco. The oil contains linalyl acetate, linalool and other terpene alcohols (sclareol), as well as their acetates.
Study NCT05129852 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reiki group
Description: Within complementary and integrative health practices, Reiki is an ancient practice of Japanese origin widely used worldwide. Through the touch or approximation of the hands, an enabled therapist applies this technique to eliminate toxins, to balance the organism, and to favor the full functioning of the organism, to reestablish the flow of vital energy. Reiki as bioenergy therapy works with the energy that leads the human body to a calmer state that is linked to health and cure. Reiki therapists conduct the curing energy that enters the top of the head and leaves through the hands.
Study NCT06105983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sisunatovir
Description: Single Dose
Study NCT06105983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sisunatovir
Description: Single Dose
Study NCT06105983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole 40 mg
Description: Tablets once daily for 7 days
Study NCT06105983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole 40 mg
Description: Tablets once daily for 7 days
Study NCT06105983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sisunatovir suspension
Description: Tablets once daily for 7 days
Study NCT05119634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole body vibration training
Description: participants will receive whole body vibration training 3 days in a week and for 8 weeks
Study NCT05119634 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: home based exercises
Description: participants will receive a home based exercise program for 8 weeks
Study NCT06105983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sisunatovir suspension
Description: Tablets once daily for 7 days
Study NCT06105983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Description: Tablets once daily for 7 days
Study NCT05863546 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Traditional treatment
Description: The patients received traditional physical therapy treatment for carpal tunnel syndrome, in the form of hot packs, tendon and nerve glide exercises, and wrist splint for 4 weeks.
Study NCT05863546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional treatment
Description: The patients received traditional physical therapy treatment for carpal tunnel syndrome, in the form of hot packs, tendon and nerve glide exercises, and wrist splint for 4 weeks.
Study NCT05863546 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Therapeutic ultrasound
Description: US treatment sessions were performed for 6 min per session, once a day, three days a week, for a total of 4 weeks.
Study NCT05863546 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound
Description: US treatment sessions were performed for 6 min per session, once a day, three days a week, for a total of 4 weeks.
Study NCT05791604 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotics including B. lactis B420, B. lactis HN019, B. animalis Bb-12, L. rhamnosus GG
Description: Take probiotics, 2g each time, twice a day, for 12 weeks
Study NCT05791604 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotics with galactomannan and oligofructose
Description: Take probiotics, 2g each time, twice a day, for 12 weeks Take prebiotics, 25g each time, twice a day, for 12 weeks
Study NCT04817007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986158
Description: Specified dose on specified days
Study NCT04817007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Specified dose on specified days
Study NCT04817007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fedratinib
Description: Specified dose on specified days
Study NCT04797130 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hospital Fit 2.0
Description: HF consists of a smartphone app combined to an accelerometer. HF provides patients and physiotherapists direct feedback on patients' physical activity behavior.. Individual goals regarding the number of minutes per day spent walking can be set by the therapist. HF also shows patients insight into their own recovery progress. During every treatment, the physiotherapist will evaluate the extent of functional recovery. In addition, Hospital Fit will give physiotherapists the option of creating a patient-specific exercise program supported by videos. During every treatment session, the patient and physiotherapist will evaluate (and if necessary adapt) the amount of activity performed since the previous treatment, the extent of functional recovery and the exercise program.
Study NCT06354803 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: proprioceptive training
Description: Proprioceptive training using swiss ball for 12 sessions
Study NCT05640453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Patients will receive pregabalin capsules (75 mg) every 12 h for 24 hours by nasogastric tube.
Study NCT05640453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Patients will receive a bolus dose of 0.4 μg/kg dexmedetomidine (over a period of 10 to 20 min)
Study NCT05712330 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non invasive ventilation samples
Description: machine samples for bacterial culture will be performed